Abstract AIM AND OBJECTIVES: Analyzing IrAEs data provides an opportunity to investigate the impacts of targeted therapy, especially as the implementation of immunotherapy in breast cancer has enhanced survival rates. We utilized digital tools to illustrate that IrAEs, including characteristics, are essential to manage for cancer patients receiving treatment, and identifying outcomes and disparities is significantly more critical. METHODS: We examined breast cancer patients admitted to the hospital in the year 2021 (National Inpatient Sample database) and further examined IrAEs among them. IrAEs examined included dermatologic, endocrine, gastrointestinal, hepatic, neurologic, pancreatic, pulmonary, and renal. We utilized approaches—propensity score matching (PSM) and difference-in-difference (DID), and additional PSM DID combined and further multivariable generalized linear models accounting for weights—to examine the outcomes—mortality, infectious complications (mainly septicemias and healthcare-associated complications), and complicated diabetes (diabc), complicated hypertension (hypc), fluid and electrolyte disorders (fed), and depression (depre) were examined. And additionally, we examined the disparities in the outcomes. RESULTS: We examined 108,170 breast cancer patients admitted to the hospital in the year 2021, and we further observed 28,390 (26%) IrAEs among them. The mean SD age of the patients admitted to the hospital with IrAEs was 66 13.25 years. The breast cancer patients who reported with IrAEs were associated with higher odds of mortality (aOR: 1.18, 95% CI: 1.02-1.38). Compared to the high-income group, the low-income group was associated with higher mortality (1.26; 1.02-1.56). And further, those with IrAEs were associated with higher septicemias (1.33; 1.21-1.46). Compared to Whites, Blacks (1.06; 1.05-1.45), Hispanics (1.26; 1.05-1.45), and Native Americans and Others (1.26; 1.07-1.48) were associated with higher septicemias. And compared to high-income neighborhoods, low-income neighborhoods were associated with higher septicemias (aOR: 1.16; 95% CI 1.03-1.32). Similarly, the trend of IrAEs outcomes and disparities was examined among fluid and electrolyte disorders(1.66; 1.07-1.27), hypertension (1.16; 1.07-1.27), and depression (1.48; 1.36-1.6). Disparities observed (Blacks were having higher hypertension, and depression was higher among Whites compared to all other racial groups, and fed was higher among low-income groups) were examined. We additionally evaluated the impact of IRAES on individual outcomes using PSM DID. The treatment effect (TE) and the average treatment effect (ATE) were examined as specific metrics that measure the average causal influence of a treatment across breast cancer cohorts. CONCLUSION: Investigating the IrAEs in breast cancer patients is crucial, since the five-year survival rate for these patients is key for patient treatment. Consequently, the competing risks within this population are particularly significant to identify, as they fall under this framework. This marks the inaugural application of digital health techniques to investigate inequities. Black individuals, Native Americans, and low-income communities are disproportionately impacted by the new regimes. Citation Format: P. S. Satheeshkumar, S. Panginikkode, V. Gopalakrishnan, D. Kewlani, N. Alam, T. Odemuyiwa, R. Pili, P. Padhi. Digital Tool to Examine the Characteristics and Disparities Associated with Immune-Related Adverse Events (IrAEs) among Breast Cancer Outcomes abstract. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS1-03-23.
Satheeshkumar et al. (Tue,) studied this question.